Multipharma SC
1,522.8 FTEThe score of Multipharma shows with a free account.
See the score- Summary? / 5
- Solvency
- Liquidity
- Interest coverage
- Profitability
- Leverage
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Revenue +19 % Equity +33 % Total assets +42 % Headcount (avg FTE) -1 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Multipharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | €580.8m | ||||
| Net result | −€2.86m | ||||
| Equity | €128.1m | ||||
| Cash | €27.9m | ||||
| EBITDA | €10.8m | ||||
| Total assets | €274.3m |
Filed annual accounts
- Year ended 31 Dec 2025filed on 25 Jun 2026
- Year ended 31 Dec 2024filed on 23 Jun 2025
- Year ended 31 Dec 2023filed on 17 Jul 2024
- Year ended 31 Dec 2022filed on 02 Aug 2023
- Year ended 31 Dec 2021filed on 22 Jun 2022
Multipharma's financial analysis
- Solvency46.7%sector median: 37.8%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Multipharma
Multipharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0866.855.346
- VAT number
- BE0866855346
- Peppol
- Registered · 0208:0866855346 · as of 19 Oct 2026
- Legal form
- SC
- Incorporated
- 19 Aug 2004
- Registered office
- 1070 Anderlecht
- Size
- Large · 1,522.8 FTE
- Latest accounts
- 2025 · filed on 25 Jun 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Multipharma (SC) has been based in Anderlecht since 2004, active in: retail sale of pharmaceutical products. For 2025, it reports revenue of €580.8m, a net loss of €2.86m and equity of €128.1m. With 1,522.8 full-time equivalents, it is a large enterprise by headcount. Its solvency stands at 46.7%, above the median of its sector (37.8%).
Companies similar to Multipharma
Companies in the same business, of comparable size and area, outside its group.
- MEDI-MARKET Parapharmacies Retail sale of pharmaceutical products Evere · balance sheet €171.3m
- Flen Health Pharma Manufacture of pharmaceutical preparations Kontich · balance sheet €15.6m
- BePharBel Manufacturing Manufacture of basic pharmaceutical products Courcelles · balance sheet €27.4m
- BENU Management Retail sale of pharmaceutical products Wavre · balance sheet €163.0m
- Sodiap Retail sale of pharmaceutical products Izegem · balance sheet €80.5m
- Philips Belgium Commercial Wholesale of pharmaceutical and medical goods Jette · balance sheet €33.0m
- Silesam Activities of holding companies Roeselare · balance sheet €42.5m
- Wisli Invest Activities of holding companies Beernem · balance sheet €28.4m
Frequently asked questions about Multipharma
What is the revenue of Multipharma?
According to the 2025 annual accounts filed with the NBB, the revenue of Multipharma amounts to 580,840,320 €.
What is the VAT number of Multipharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0866855346 for Multipharma, if the company is VAT-registered. Its company number (CBE) is 0866.855.346.
Where is the registered office of Multipharma?
According to the CBE register, the registered office of Multipharma is in 1070 Anderlecht.
What is the equity of Multipharma?
At the close of the 2025 financial year, the equity of Multipharma amounts to 128,100,759 €, a solvency of 46.7% of total assets.
How many people work at Multipharma?
1,522.8 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Multipharma?
The register lists 7 active mandates at Multipharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Multipharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →